Lupin Awarded EcoVadis Silver Medal for Sustainability Excellence, Ranks Among the Top 15% Globally

Mumbai, March 20, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has been awarded “Silver Medal” by EcoVadis for its outstanding sustainability management practices in areas such as Environment, Labor and Human Rights, Ethics and Sustainable Procurement. This prestigious achievement places Lupin amongst the top 15% of companies evaluated by EcoVadis.

EcoVadis is a globally trusted provider of business sustainability ratings with a network of more than 150,000 companies being rated. The EcoVadis sustainability assessment methodology evaluates the integration of sustainability principles effectively into a company’s business and management system. Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring, moving up from 51 in 2024 to 69 in 2025. With this achievement, Lupin is positioned at the 87th percentile in the 2025 assessment.

Commenting on the achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin said, “This milestone is a reaffirmation of our commitment to developing superior, cost-effective pharmaceutical products and enabling robust supply chain practices that prioritize environmental sustainability. We, along with our partners, are committed to ensuring that every product we manufacture propels us towards building a sustainable future and a healthier planet, while enhancing value for all our stakeholders.”

Earlier this year, Lupin received an “A-” leadership rating from CDP for its outstanding performance in climate change and water security. Additionally, Lupin’s S&P Global ESG scores moved to 76 from 69 last year, above the industry average of 30 in the pharmaceuticals sector.

About Lupin  
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. 
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin    

For further information or queries please contact:
Rajalakshmi Azariah 
Vice President & Global Head – Corporate Communications, Lupin  
rajalakshmiazariah@lupin.com